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Abstract
Recurrent small-cell lung cancer (SCLC) has limited chemotherapy options. Here, we report the outcome of the
first trial of arginine-deprivation therapy (pegargiminase, ADI-PEG 20) in patients with relapsed/refractory SCLC.
The best overall response to pegargiminase in SCLC was stable disease. Recent molecular stratification including
MYC status and immune checkpoint blockade may leverage arginine-lowering therapy in SCLC going forward.
Background: Pre-clinical studies indicated that arginine-deprivation therapy using pegylated arginine deiminase
(pegargiminase, ADI-PEG 20) may be effective in patients with argininosuccinate synthetase 1 (ASS1)-deficient small-
cell lung cancer (SCLC). Patients and Methods: Patients were enrolled into either a ‘sensitive’ disease cohort ( 90
days response to first-line chemotherapy) or a ‘refractory’ disease cohort (progression while on chemotherapy or < 90
days afterwards or  third-line treatment). Patients received weekly intramuscular pegargiminase, 320 IU/m2 (36.8 mg/
m2), until unacceptable toxicity or disease progression. The primary endpoint was tumor response assessed by
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with secondary endpoints including tolerability, pharma-
codynamics, and immunogenicity. Results: Between January 2011 and January 2014, 22 patients were enrolled: 9 in
the sensitive disease cohort and 13 in the refractory disease cohort. At a pre-planned interim analysis, the best overall
response observed was stable disease in 2 patients in each cohort (18.2%). Owing to the lack of response and slow
accrual in the sensitive disease cohort, the study was terminated early. Pegargiminase treatment was well-tolerated
with no unexpected adverse events or discontinuations. Conclusion: Although pegargiminase monotherapy in
SCLC failed to meet its primary endpoint of RECIST-confirmed responses, more recent molecular stratification,
including MYC status, may provide new opportunities moving forward.
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An estimated 1.6 million new lung cancers are diagnosed every
year with small-cell lung cancer (SCLC) accounting for around
13% of cases.1 Primary SCLC is associated with a cigarette-
smoking history and derives from neuroendocrine precursor
cells. SCLC is typified by a rapid proliferation rate together with a
high response rate (w70%) to chemotherapy in the first-line
setting.1,2 However, the majority of patients with extensive
SCLC will relapse with a median progression-free survival (PFS)
of 5.5 months and a median overall survival of 9.6 months.3
Response rates to second-line treatment are much poorer, being
around 10% for patients with refractory disease (< 3 months
treatment-free interval) and 20% for patients with sensitive dis-
ease (> 3 months).1Clinical Lung Cancer Month 2020 - 1
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Efficacy of ADI-PEG 20 in SCLCAuxotrophy is the inability of an organism to synthesize an
organic compound necessary for its growth.4 At the cellular level,
this has been exploited in the treatment of T-cell acute lympho-
blastic leukemia (T-ALL) by the use of L-asparaginase. T-ALL cells
are auxotrophic for asparagine owing to a lack of the enzyme
asparagine synthetase, in contrast to normal cells.5,6 Similarly, many
tumor types have been found to be auxotrophic for arginine.
Arginine is involved in the regulation of multiple cellular pathways,
including proliferation via polyamines and mammalian target of
rapamycin signaling, and as the precursor for nitric oxide involved
in endothelial, immune, and neuronal cell biology.7 Normal cells
contain argininosuccinate synthetase 1 (ASS1), which converts
citrulline to arginine, thereby providing an endogenous supply.
However, many tumors downregulate ASS1, forcing them to be
dependent on exogenous arginine (ie, arginine auxotrophic).8-11
This has been studied most extensively in hepatocellular carci-
noma (HCC) and melanoma, but has also been identified in a range
of other tumor types.7,12 An important mechanism of ASS1
downregulation is hypermethylation of the promoter, first identified
in mesothelioma, although other mechanisms also play a role,
including promoter repression by hypoxia-inducible factor-1a.11,13
Downregulation of ASS1 leads to aspartate being shunted into
increased pyrimidine synthesis and thereby tumor proliferation;
thus bypassing the production of argininosuccinate and urea.14
Notably, downregulation of ASS1 leads to a dependence on exog-
enous arginine that can be exploited therapeutically by catabolizing
enzymes. One such approach is via arginine deiminase (ADI), which
catalyzes the irreversible conversion of L-arginine to citrulline and
an ammonium ion.15 This was identified from Mycoplasma species
and inhibited tumor growth in vitro.16,17 However, in vivo, it is
highly immunogenic with a short serum half-life, both of which
were improved by conjugating ADI to polyethylene glycol (20,000
Da; ADI-PEG 20; pegargiminase).18 The initial phase I/II trials
were undertaken in HCC and melanoma owing to their high fre-
quency of ASS1 loss.19,20 Pharmacodynamic results showed that
serum arginine was reduced to an undetectable level within 24
hours of the first ADI-PEG 20 injection and persisted for at least 7
days. The initial response rates in HCC and melanoma were
promising, with no grade 3 or 4 toxicity observed from ADI-PEG
20.19,20 Loss of ASS1 is a potential predictive biomarker to argi-
nine deprivation therapy, with 53% of ASS1-deficient patients
treated with ADI-PEG 20 having either a partial response or stable
disease (SD) compared with 10% of ASS1-proficient patients with
melanoma (P ¼ .041).10
Pre-clinical data using SCLC cell lines and xenografts showed
that 45% to 50% of tumors were negative for ASS1.21 ADI-PEG 20
reduced the growth of ASS1, but not ASS1þ, cell lines in vitro.
Similarly, arginine deprivation led to a dose-dependent reduction in
the size of ASS1 xenografts in vivo, whereas ASS1þ xenografts
were resistant.21 Therefore, the efficacy and safety of ADI-PEG 20
was examined in patients with ASS1-deficient SCLC.
Materials and Methods
Patients
Eligible patients were 18 years of age or older with histologically
confirmed SCLC in which < 5% of tumor cells expressed ASS1 as
determined by immunohistochemistry (0 or 1þ by ASS1nical Lung Cancer Month 2020immunohistochemistry using mAb 195-21-1 from Polaris Phar-
maceuticals, Inc, San Diego, CA). ASS1 levels were determined on
archival tissue samples. Eligible patients must have had at least 1
previous line of chemotherapy prior to enrollment and have re-
fractory/relapsed disease that was measurable by Response Evalua-
tion Criteria in Solid Tumors (RECIST) 1.1.22 Patients had an
Eastern Cooperative Oncology Group performance status of  2 as
well as adequate hematologic, renal, and hepatic function. Exclusion
criteria included metastatic disease to the central nervous system,
unless treated and stable, as well as a history of seizures. Prior
treatment with ADI-PEG 20 was not allowed.
Study Design
This was an open-label, 2-arm, non-randomized phase II study
conducted across 8 centers in the United States, Taiwan, the United
Kingdom, Germany, and Belgium. Cohort 1 enrolled patients with
‘sensitive’ disease who had maintained an appropriate response for
90 days or more after 1 previous line of chemotherapy. Cohort 2
enrolled patients with ‘refractory’ disease who had either progressed
while on chemotherapy or within 90 days of completing treatment.
Patients who required a third line of treatment, irrespective of the
response duration to the initial 2 lines of chemotherapy (ie, sensitive
or refractory), were also enrolled in Cohort 2. Each cohort was to be
enrolled in 2 stages. In the first stage, 15 patients were to be enrolled
in Cohort 1 and 12 patients in Cohort 2. If 3 or more patients met
the primary endpoint (tumor response) in Cohort 1, then an
additional 13 patients were to be accrued. If 2 or fewer patients met
the primary endpoint in Cohort 1, then the study would be
terminated and declared negative for this cohort. For Cohort 2, 1 or
more patients had to meet the primary endpoint for an additional 4
patients to be accrued. If no patients achieved the primary endpoint
in Cohort 2, then the study would be terminated and declared
negative.
Treatment
Both cohorts received the same treatment regimen, consisting of
4 weekly intramuscular administrations of ADI-PEG 20, 320 IU/
m2 (36.8 mg/m2) followed by a 1-week follow-up (1 cycle) as
defined by earlier phase I/II studies.19,20,23 No dose adjustment was
allowed. If toxicity warranted a delay of 4 or more days, then the
dose was omitted. Patients were withdrawn if 2 consecutive doses
were omitted. Additional treatment cycles were permitted in the
absence of disease progression requiring other therapeutic
interventions.
End Points and Assessments
The primary endpoint for clinical efficacy was tumor response,
defined as complete response (CR) or partial response (PR) as
assessed by RECIST 1.1. Tumors could be assessed using any
appropriate imaging. Tumor assessments could occur every 4 to 8
weeks, depending on local standard practice.
Secondary endpoints were the safety and tolerability of ADI-PEG
20 (assessed using National Cancer Institute Common Terminology
Criteria for Adverse Events [NCI-CTCAE] version 4.0); to measure
changes in the plasma arginine and citrulline levels associated with
ADI-PEG 20 treatment; to investigate the association between
plasma arginine and citrulline levels and the primary endpoint; to
Table 1 Demographic Characteristics at Baseline
All Patients (n [ 22), n (%)
Age, y
Median (range) 62.5 (49-83)
Gender
Male 14 (64)
Female 8 (36)
Country
United States 11 (50)
Taiwan 6 (27)
United Kingdom 3 (14)
Germany 1 (4.5)
Belgium 1 (4.5)
Race
White 14 (64)
Asian 6 (27)
Black or African heritage 1 (4.5)
Unknown 1 (4.5)
ASS1 assay result
Negative 11 (50)
<5% cells positive 11 (50)
Abbreviation: ASS1 ¼ argininosuccinate synthetase 1
Peter E. Hall et alinvestigate the immunogenicity of ADI-PEG 20 by measuring anti-
ADI-PEG 20 antibodies over time; and to estimate overall survival
(measured from initial date of treatment).
Statistical Analysis and Ethical Considerations
The sample size for each cohort was determined through a Simon
2-stage Minimax design with type I error and type II error set to
0.05 and 0.2, respectively.
In Cohort 1, patients with sensitive disease, a 15% response rate
was considered not promising (based on a pooled analysis assessing
the efficacy of current standard treatment, topotecan, that indicated
a response rate of 18%), and a 35% response rate was considered
promising. A minimum of 15 and a maximum of 28 subjects were
to be enrolled in this cohort.
In Cohort 2, patients with refractory disease and any patient in
need of third-line therapy, a 5% response rate was considered not
promising (based on there being no established effective treatment
for these patients), but a 25% response rate was considered prom-
ising. A minimum of 12 and a maximum of 16 patients were to be
enrolled in this cohort.
All statistical analyses were performed using Statistical Analysis
Software (SAS) Version 9.2 or higher for Windows.
The study was performed in accordance with good clinical
practice and Institutional Review Board approval. All patients
provided written informed consent. ClinicalTrials.gov number
NCT01266018.
Results
Patients
Between January 2011 and January 2014, 22 patients were
enrolled; 9 with sensitive disease and 13 with refractory disease,
across 8 international sites. The age range was 49 to 83 years, with a
median of 62.5 years (Table 1). Fourteen (64%) patients were male,
and 11 (50%) were recruited from the United States, with 6 (27%)
from Taiwan, 3 (14%) from the United Kingdom, and 1 (4%) each
from Belgium and Germany. Eleven (50%) patients were negative
for ASS1, and 11 (50%) had < 5% cells positive.
Tumor Response
No patient had a CR or PR as their best overall response. Two
(22%) patients in the sensitive disease cohort and two (15%) in the
refractory disease cohort had a best overall response of SD or 18.2%
(4/22) overall. One patient with SD in the refractory disease cohort
had a biochemical response as assessed by a drop in serum lactate
dehydrogenase during the first month of ADI-PEG 20 therapy. The
remainder had progressive disease. One patient was withdrawn from
the sensitive disease cohort as it was determined that it was in the
best medical interests of the patient by the investigator, and one was
withdrawn from the refractory cohort owing to clinical evidence of
disease progression. As such, both patients were non-evaluable with
regard to the primary endpoint.
As no patient in the refractory cohort had a radiologic response to
ADI-PEG 20, thereby failing to meet the pre-specified interim
analysis criteria for further accrual, and there was poor recruitment
to the sensitive disease cohort, the study was terminated early.
Overall survival was not analyzed owing to the premature termi-
nation of the study.Tolerability and Safety
The median treatment duration was 6.1 weeks in the sensitive
cohort (range, 0.1-7.0 weeks) and 2.1 weeks (range, 0.1-15.1 weeks)
in the refractory disease cohort. Similarly, the median number of
doses received was 6.0 (range, 1-8) in the sensitive disease cohort
and 3.0 (range, 1-16) in the refractory disease cohort. This is in line
with expectations as the sensitive disease group, by definition, had
responded to previous chemotherapy and therefore probably had
less aggressive disease.
The administration of ADI-PEG 20 320 IU/m2 to patients with
SCLC was not associated with adverse events (AEs) or laboratory
abnormalities that were unexpected (Table 2). AEs of any type were
reported in 21 (95%) of the 22 patients with 6 (27%), 3 (14%), and
3 (14%) patients experiencing grade 3, 4, or 5 events, respectively.
Ten (45%) patients experienced serious AEs. AEs were assessed as
being treatment-related in 12 (54%) patients. Three (14%) patients
had their treatment discontinued owing to AEs related to disease
progression.
The most common AEs of any grade were fatigue (10 patients;
45%), decreased appetite (7 patients; 32%), and dyspnea (5 pa-
tients; 23%). Nine (41%) patients experienced at least 1 grade 3 to
4 AE. Of these AEs, 10 related to decreased blood cell counts
(including febrile neutropenia) and were experienced by 3 (14%)
patients. The remainder were dyspnea (4 patients; 18%), cough (1
patient; 4.5%), somnolence (1 patient; 4.5%), asthenia (1 patient;
4.5%), and non-cardiac chest pain (1 patient; 4.5%). The most
common treatment-related AEs of any grade were fatigue (5 pa-
tients; 23%), leukopenia (3 patients; 14%), neutropenia (3 patients;
14%), injection site reaction (3 patients; 14%), decreased appetite
(3 patients; 14%), and nausea (3 patients; 14%). Four (18%)Clinical Lung Cancer Month 2020 - 3
Table 2 Reported Adverse Events Based on the Common Terminology Criteria for Adverse Events (CTCAE 4.0)
Adverse Event
All Reported Events Treatment-related Events
All Grades, n (%) Grade 3-4, n (%) All Grades, n (%) Grade 3-4, n (%)
Any 21 (95) 9 (41) 12 (54) 4 (18)
Constipation 4 (18) 0 (0) 0 (0) 0 (0)
Nausea 4 (18) 0 (0) 3 (14) 0 (0)
Vomiting 4 (18) 0 (0) 2 (9) 0 (0)
Diarrhea 3 (14) 0 (0) 2 (9) 0 (0)
Fatigue 10 (45) 0 (0) 5 (23) 0 (0)
Asthenia 4 (18) 1 (4.5) 0 (0) 0 (0)
Neutropenia 3 (14) 3 (14) 3 (14) 3 (14)
Leukopenia 4 (18) 3 (14) 3 (14) 3 (14)
Lymphopenia 1 (4.5) 1 (4.5) 1 (4.5) 1 (4.5)
Thrombocytopenia 3 (14) 2 (9) 2 (9) 2 (9)
Febrile neutropenia 1 (4.5) 1 (4.5) 1 (4.5) 1 (4.5)
Decreased appetite 7 (32) 0 (0) 3 (14) 0 (0)
Dysgeusia 2 (9) 0 (0) 2 (9) 0 (0)
Dyspnea 5 (23) 4 (18) 0 (0) 0 (0)
Cough 4 (18) 1 (4.5) 0 (0) 0 (0)
Wheezing 3 (14) 3 (14) 0 (0) 0 (0)
Somnolence 1 (4.5) 1 (4.5) 0 (0) 0 (0)
Non-cardiac chest pain 1 (4.5) 1 (4.5) 0 (0) 0 (0)
Pruritis 2 (9) 0 (0) 2 (9) 0 (0)
Injection site reaction 3 (14) 0 (0) 3 (14) 0 (0)
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4 - Clipatients had treatment-related AEs at a maximum grade of 3 or 4
(none had grade 5) that were all related to low blood cell counts,
including 1 episode of febrile neutropenia. In 1 patient, hematologic
toxicity was exacerbated by receiving 2 accidental overdoses of ADI-
PEG 20. Injection-related AEs occurred in 3 (14%) patients and
were all grade 1 in severity. Three (14%) patients, all in the re-
fractory disease cohort, had the study drug withdrawn owing to
disease progression. Three patients died within 30 days of the last
administration of the study drug. The causes were reported as dis-
ease progression in 2 patients and cardiac arrest in 1 patient, with
none assessed as being related to ADI-PEG 20.
Hematologic testing showed a tendency for neutrophil,
lymphocyte, and white blood cell counts to mildly decrease (grade 1
or less) by cycle 1, day 15, and then to recover to their baseline
levels by day 29. In previous clinical trials of ADI-PEG 20, increases
in amylase, lipase, uric acid, and liver transaminases were seen. In
this study, the number of patients tested at baseline for amylase (6
of 9 patients in the sensitive disease cohort) and lipase (5 patients in
the sensitive disease cohort and 1 patient in the refractory disease
cohort) were too small to draw any meaningful conclusion. No
notable changes in any other clinical chemistry test, including uric
acid, alanine aminotransferase, and aspartate aminotransferase, were
seen apart from the decrease in serum lactate dehydrogenase
described above, and identified as a treatment-related effect.
Pharmacodynamics and Immunogenicity
The arginine, citrulline, and anti-ADI-PEG 20 antibody levels
were determined for 21 (95%) patients with available plasma
samples. A total of 121 plasma samples were assessed. No signifi-
cance difference in the pharmacodynamics was seen between the 2nical Lung Cancer Month 2020cohorts (Figure 1). Weekly treatment with ADI-PEG 20 320 IU/m2
(36.8 mg/m2) was sufficient to reduce plasma arginine levels to <
50% baseline for approximately 50 days, with a reciprocal rise in
citrulline levels. However, by day 58 (the last day for which samples
were analyzed), the mean arginine and citrulline levels were trending
back towards their baseline levels. These changes correlated with the
appearance of antibodies against ADI-PEG 20.
Discussion
This phase II study of arginine deprivation by ADI-PEG 20 in
patients with relapsed or refractory SCLC failed to meet its
primary endpoint, with no objective responses to treatment seen.
This, coupled with slow accrual in the sensitive disease cohort,
led to the trial being terminated early. The AEs seen in this study
were expected for the study population and ADI-PEG 20 ther-
apy. No patients discontinued owing to treatment-related AEs,
and no deaths were attributable to the study drug. Fatigue,
decreased appetite, and leucopenia were the most common
treatment-related AEs, in line with the findings of other
studies.24,25
The lack of objective responses is consistent with recent trials
using ADI-PEG 20 monotherapy in other tumor types. Although a
small-scale phase I/II trial with 19 patients suggested a meaningful
response rate in HCC, this was not borne out in larger phase II and
III trials with objective response rates of 0.5% to 3%.19,25,26
Similarly, a randomized phase II study in ASS1-deficient malig-
nant pleural mesothelioma (MPM) failed to record any objective
responses.24 However, an improvement in PFS of 1.2 months was
seen in ADI-PEG 20-treated patients with mesothelioma compared
with best supportive care alone (P ¼ .03), highlighting that
Figure 1 Pharmacodynamics and Immunogenicity Studies. The Mean Arginine Levels (Top), Citrulline Levels (Middle), and Serum
Levels of anti-ADI-PEG 20 (Bottom) for Patients Treated With ADI-PEG 20 in the Sensitive Disease Cohort (Cohort 1), the
Refractory Disease Cohort (Cohort 2) and Both Cohorts Combined (All) are Shown by Day on Study
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Peter E. Hall et alresponse rate alone may be insensitive in measuring the activity of
arginine-depleting agents. Moreover, post-hoc analysis revealed that
the PFS improvement was proportional to the degree of ASS1
deficiency, with > 75% loss being associated with the best survival
outcomes compared with > 50% to 75% deficiency.24 This SCLC
study required > 95% loss of ASS1 expression, indicating that this
is unlikely to be the reason for the negative outcome.Furthermore, the duration of arginine deprivation has been
linked to overall survival, with prolonged arginine deprivation
beyond 4 weeks linked to better outcomes across studies in mela-
noma, HCC, and MPM.10,23,27 In this small study, the duration
patients spent on pegargiminase therapy varied most notably in the
refractory SCLC disease cohort (up to 16 weeks). This may indicate
that there is a subgroup of ASS1-deficient patients with SCLC whoClinical Lung Cancer Month 2020 - 5
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6 - Cliderive more benefit from pegargiminase and warrant further
investigation. Indeed, one possibility is that these represent the
MYC-driven variant SCLC subgroup characterized recently as
exquisitely sensitive to ADI-PEG 20 using patient-derived xeno-
grafts of SCLC.28 In contrast, cells of the more common classic or
MYCL-driven subtype were resistant to arginine deprivation.28
Unfortunately, owing to limited material from patients enrolled in
this study, retrospectively testing for MYC status was not feasible.
However, future studies of pegargiminase, at least potentially for
monotherapy, would require SCLC molecular subtyping rather than
ASS1 status alone in patient selection.29
Antibodies to ADI-PEG 20 appeared by day 50, consistent with
prior monotherapy ADI-PEG 20 studies.23,26,30,31 These may act to
limit the efficacy of ADI-PEG 20. Other resistance mechanisms
have been described, including re-expression of ASS1 via hypoxia-
inducible factor-1a as well as autophagy.13,21 Increased autophagy
has been observed in SCLC cells in vitro in response to ADI-PEG
20 treatment and may provide a means of supplying arginine when
exogenous levels are low.21 Similarly, the tumor microenvironment
has been implicated in supplying amino acids when exogenous levels
are low, either through micropinocytosis or stromal cells.12,32,33
Therefore, multiple mechanisms exist to maintain arginine ho-
meostasis when plasma levels are low, and consequently pegargi-
minase alone, as with asparaginase monotherapy for T-ALL, will be
limiting as a single agent. This is supported by the first phase III
study of ADI-PEG 20 monotherapy in second-line treatment of
advanced HCC that did not show a PFS or overall survival
advantage versus placebo.25
There is a biochemical rationale for combining ADI-PEG 20
with chemotherapy. ASS1 positivity is associated with sensitivity to
platinum chemotherapy, whereas ASS1 loss is a predictor of resis-
tance.34-36 Loss of ASS1 correlates with increased levels of thymi-
dylate synthase (TS) and dihydrofolate reductase, target enzymes of
pemetrexed chemotherapy.12 High levels of TS have been associated
with resistance to pemetrexed.37,38 ADI-PEG 20 has been
demonstrated to suppress TS and dihydrofolate reductase and
thereby potentiate the effect of pemetrexed chemotherapy.12
Therefore, given the heterogeneity of ASS1þ and ASS1 cells in
most tumors, a triplet combination of platinum plus pemetrexed
and ADI-PEG 20 may prove more effective than either doublet
chemotherapy or ADI-PEG 20 monotherapy.39 This approach has
shown promise in nonesmall-cell lung cancer, MPM, and relapsed
glioblastoma, with larger scale trials ongoing.40,41 Finally, with the
recent incremental survival benefit of combining programmed
death-ligand 1 blockade with carboplatin and etoposide as front-line
therapy for extensive SCLC, there are additional avenues that merit
further study.42,43 Specifically, pegargiminase has been shown to
induce programmed death-ligand 1 expression in tumor cell lines
and promote a T cell infiltrate in syngeneic tumour models.44
Moreover, urea cycle-deficient cancers, including functional loss
of ASS1, may be more tractable to immunometabolic strategies in
general.45 Indeed, a phase I/II study is underway of a bioengineered
form of human arginase 1, pegzilarginase, combined with pem-
brolizumab specifically in patients with relapsed SCLC
(ClinicalTrials.Gov Identifier: NCT03371979).46 In summary,
combination studies will be critical in defining the role of depleting
arginine as a novel anti-metabolite strategy for SCLC.nical Lung Cancer Month 2020Conclusion
In conclusion, the use of pegargiminase monotherapy in patients
with relapsed or refractory SCLC failed to meet its primary
endpoint, with no tumor responses seen in either cohort. Four
(18%) patients (2 in each cohort) had a best response of SD. The
study was therefore terminated early. The treatment was well-
tolerated with no unexpected AEs or discontinuations.Clinical Practice Points
 SCLC is an aggressive form of lung cancer with limited effective
treatment options after first-line chemotherapy.
 Many tumors, including 45% to 50% of SCLC, are auxotrophic
for arginine, usually via downregulation of ASS1. As such, these
tumors are unable to produce endogenous arginine and are
dependent on an exogenous supply.
 This can be exploited therapeutically using ADI-PEG 20
(pegargminase), which showed efficacy in preclinical studies
involving ASS1-deficient SCLC xenografts.
 This paper reports the first trial of ADI-PEG 20 in patients with
relapsed/refractory SCLC, recruited into a ‘sensitive’ disease
cohort ( 90 days response to first-line chemotherapy; 9 pa-
tients) or a ‘refractory’ disease cohort (progression while on
chemotherapy or < 90 days afterwards or  third-line treatment;
13 patients). The primary end point was tumor response rate by
RECIST 1.1.
 At a pre-planned interim analysis, the best overall response
observed was SD in 2 (18.2%) patients in each cohort. Owing to
the lack of objective response and to slow accrual in the sensitive
disease cohort, the study was terminated early.
 The outcome of this trial indicates that pegargiminase mono-
therapy is unlikely to be an effective treatment for recurrent/
refractory SCLC. However, recent preclinical work has indicated
that MYC status may identify a subpopulation of patients with
SCLC who are sensitive to arginine deprivation monotherapy,
and further combination trials are planned employing this
stratification biomarker.
 Additionally, arginine-lowering agents combined with immune
checkpoint blockade are being tested in the clinic, including in
SCLC, based on preclinical immunometabolic cooperation.Acknowledgments
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